echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Good news for diabetics!

    Good news for diabetics!

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Recently, Novo Nordisk’s self-developed innovative drug in the field of diabetes-insulin deglulam and liraglutide injection (Novozymes) was officially approved by the National Medical Products Administration (NMPA), which means that the drug is The world's first basal insulin glucagon-like peptide-1 receptor agonist (GLP-1RA) injection was approved in China, and a new era of China's type 2 diabetes (T2DM) treatment has officially opened! Public information shows that deglu insulin and liraglutide injection were approved by the European Medicines Agency (EMA) in September 2014 (Xultophy), and were launched in Switzerland in January 2015, becoming the world's first marketed basal insulin GLP-1RA injection Liquid

    In November 2016, it was approved by the U.
    Food and Drug Administration (FDA) (Xultophy 100/3.

    In August 2020, Novo Nordisk submitted a new drug listing application for deglu insulin and liraglutide injection in China.
    At present, no similar products have been approved for listing in China

    According to data, the number of diabetes patients in China is as high as 129.
    8 million, ranking first in the world, and only 49.
    4% of the patients undergoing treatment reach the standard, which is not ideal

    Poor blood glucose control for a long time is prone to various complications, which not only affects the quality of life of patients, but also increases the economic burden of the family and society

    Insulin therapy is one of the important methods of blood sugar control.
    At present, there are still unmet needs such as late initiation of insulin therapy, fear of injections, hypoglycemia, weight gain, complex treatment plans, and poor compliance

    Innovative insulin drugs have always been expected and concerned, and the combination therapy of basal insulin and GLP-1RA provides a new direction

    Insulin deglulam and liraglutide injection have been written into the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)".
    Its approval in China has opened up a whole new situation for the management of T2DM patients and is expected to help the majority of patients further Increase the rate of compliance and reduce the physical and mental burden

    At present, two similar products have been approved for type 2 diabetes worldwide.
    In addition to Novo Nordisk's products, there is also Sanofi's Soliqua 100/33

    The latter is a fixed-ratio combination of risnatide/insulin glargine, which was approved by the FDA on the same day as Xultophy, and its global sales in 2020 will be approximately US$184 million

    According to the Insight database, Sanofi's products have just been declared for listing on September 30

    In addition, China Hengrui Pharmaceuticals, a domestic company, also has similar products under development

    Its self-developed long-acting insulin/GLP-1 analog fixed ratio compound preparation HR17031 injection has been approved for clinical trials in China and the United States in July this year

    End reference materials: [1]https:// for the first time in the past! Pig kidneys have been successfully used for human transplantation.
    These companies have already "run away" the hot literature life is "saving" from the mouth? Nature sub-Journal: In fact, "when to eat" is more important than "eat less" in the history of hot literature The strong "food compass" is here! See how unhealthy the things you usually like to eat.
    Rewen stayed up all night and had a heart break! Nature Sub-Journal: Staying up late disrupts the circadian rhythm of the heart, increases the risk of sudden death, and adds scientific evidence that there is no need for a kidney transplant! Nature Sub-Journal: Scientists Reveal the Plasticity of the Kidney by Reversing Polycystic Kidney Disease in Mice Medical Immunotherapy Research/Translational Medicine Leukemia| Lung Cancer| Stomach Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Diseases| Neurodegenerative Diseases| Intestinal Microbiological Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Printing | Genetic testing | Single cell sequencing | Gene editing | Assisted reproduction | Artificial intelligence | Precision medicine policy Anti-cancer drugs | 4+7 volume procurement | Consumables | Record system | Registrant system | Healthy China | New version of the basic drug catalog | AI medical Equipment | Telemedicine | Same-share market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D investment |
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.